argenex SE $ARGX Shares Bought by Simplify Asset Management Inc.

Simplify Asset Management Inc. lifted its stake in shares of argenex SE (NASDAQ:ARGX) by 87.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,115 shares of the company’s stock after purchasing an additional 1,456 shares during the period. Simplify Asset Management Inc.’s holdings in argenex were worth $2,620,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the stock. William Blair Investment Management LLC bought a new position in shares of argenex during the fourth quarter worth about $188,071,000. Life Cycle Investment Partners Ltd bought a new position in shares of argenex during the fourth quarter worth about $38,537,000. EverSource Wealth Advisors LLC lifted its position in shares of argenex by 17.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 205 shares of the company’s stock worth $172,000 after purchasing an additional 30 shares during the last quarter. Keudell Morrison Wealth Management bought a new position in shares of argenex during the fourth quarter worth about $426,000. Finally, Global Retirement Partners LLC lifted its position in shares of argenex by 582.2% during the fourth quarter. Global Retirement Partners LLC now owns 730 shares of the company’s stock worth $614,000 after purchasing an additional 623 shares during the last quarter. Institutional investors own 60.32% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. HC Wainwright increased their price target on shares of argenex from $915.00 to $940.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of argenex in a research report on Monday, April 20th. Guggenheim increased their price target on shares of argenex from $1,120.00 to $1,135.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Wedbush reaffirmed an “outperform” rating and set a $1,000.00 price target on shares of argenex in a research report on Monday, March 9th. Finally, Royal Bank Of Canada cut their target price on shares of argenex from $925.00 to $890.00 and set an “outperform” rating on the stock in a report on Friday, February 27th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, argenex currently has a consensus rating of “Moderate Buy” and an average target price of $1,017.78.

argenex Price Performance

Shares of NASDAQ ARGX opened at $806.46 on Monday. The firm’s 50-day moving average price is $767.17 and its two-hundred day moving average price is $815.79. argenex SE has a 52-week low of $510.05 and a 52-week high of $934.62. The stock has a market capitalization of $49.90 billion, a P/E ratio of 35.91, a P/E/G ratio of 1.28 and a beta of 0.46.

argenex (NASDAQ:ARGX) last issued its earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share (EPS) for the quarter. argenex had a net margin of 31.31% and a return on equity of 33.28%. The firm had revenue of $1.31 billion for the quarter. As a group, equities research analysts expect that argenex SE will post 25.27 earnings per share for the current year.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.